institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 3 days ago • loading... • Updated 3 days ago

UK price watchdog recommends against Amgen's Lumakras in lung cancer

Summary by endpoints.news

The UK’s drug pricing watchdog said government reimbursement of Amgen’s lung cancer drug Lumakras should be cut off for new patients. In draft guidance released on Thursday, the National Institute for Health and Care Excellence ...

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

2 Articles

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.

4 days ago

Read Full Article

UK price watchdog recommends against Amgen's Lumakras in lung cancer

The UK’s drug pricing watchdog said government reimbursement of Amgen’s lung cancer drug Lumakras should be cut off for new patients. In draft guidance released on Thursday, the National Institute for Health and Care Excellence ...

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources2

Leaning Left0Leaning Right0Center1Last Updated3 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmaphorum broke the news 4 days ago on Thursday, July 9, 2026.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics